Provided by Tiger Trade Technology Pte. Ltd.

Harrow Health Inc

34.08
+0.80002.40%
Volume:438.75K
Turnover:14.91M
Market Cap:1.27B
PE:-243.43
High:34.87
Open:34.87
Low:33.03
Close:33.28
52wk High:54.85
52wk Low:20.85
Shares:37.23M
Float Shares:27.23M
Volume Ratio:0.84
T/O Rate:1.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1400
EPS(LYR):-0.1400
ROE:-8.47%
ROA:4.84%
PB:24.19
PE(LYR):-243.43

Loading ...

Harrow Price Target Maintained With a $63.00/Share by BTIG

Dow Jones
·
Mar 19

Harrow to present three abstracts at ASCRS 2026 Annual Meeting

Reuters
·
Mar 18

These Analysts Revise Their Forecasts On Harrow Following Q4 Results

Benzinga
·
Mar 04

Harrow price target lowered to $91 from $94 at Cantor Fitzgerald

TIPRANKS
·
Mar 04

Harrow Is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Mar 04

Harrow Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 04

Harrow to present at Leerink Partners 2026 Global Healthcare Conference in Miami

Reuters
·
Mar 04

Harrow price target raised to $70 from $69 at H.C. Wainwright

TIPRANKS
·
Mar 04

Opaleye Management Inc. reports disposal of Harrow Inc. common shares

Reuters
·
Mar 04

Harrow Down Over 27%, on Pace for Largest Percent Decrease Since November 2023 -- Data Talk

Dow Jones
·
Mar 04

Top Midday Decliners

MT Newswires Live
·
Mar 04

BUZZ-U.S. STOCKS ON THE MOVE-Versant Media Group, Lithium miners, Expedia Group

Reuters
·
Mar 04

Harrow Stock Plunges on 4Q Earnings Miss, Conservative Outlook

Dow Jones
·
Mar 04

BUZZ-U.S. STOCKS ON THE MOVE-Expedia Group, Blue Owl Capital, Enphase Energy

Reuters
·
Mar 03

Analysts Are Bullish on These Healthcare Stocks: Harrow Health (HROW), Atai Beckley N.V. (ATAI)

TIPRANKS
·
Mar 03

Stock Track | Harrow Health Plummets 19.59% in Pre-Market on Earnings Miss and Below-Estimate 2026 Revenue Guidance

Stock Track
·
Mar 03

Harrow Shares Plunge 19% After Co Forecasts 2026 Revenue Below Estimates

THOMSON REUTERS
·
Mar 03

Why Is Eye-Disease-Focused Harrow Stock Falling Today?

Benzinga
·
Mar 03

BRIEF-Harrow To Initiate Phase 3 Clinical Trial Seeking To Expand Triesence® Label To Include Ocular Inflammation And Pain Following Cataract Surgery Indication

Reuters
·
Mar 03

Harrow announces U.S. FDA cleared an IND application for trial of Triesence

TIPRANKS
·
Mar 03